ClinicalTrials.gg
Status unknownNCT04970433Updated Mar 31, 2022

The Effects of Acupuncture for Major Trauma

An interventional study of Electroacupuncture (EA) and Laser acupuncture (LA) in Major Trauma, sponsored by Chang Gung Memorial Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

Major trauma is a significant cause for morbidity and mortality in the world. After traumatic injury, the damage tissue could induce systemic inflammatory response (SIRS) and activate autonomic nervous system in response to stress, followed by compensatory anti-inflammatory response (CARS). Imbalance of SIRS and CARS may lead to organ failures, sepsis and death.

Read the detailed description

The investigators design a prospective clinical trial to investigate the efficacy of acupuncture for major trauma.

02

Conditions studied

  • Major Trauma

Keywords

  • major trauma
  • acupuncture
  • laser acupuncture
03

In context

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,091 studies on the registry; 237 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 20 years or older
  • Confirmed diagnosis of major trauma with ISS ≥ 16

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Malignancy
  • Pacemaker
  • Status epilepticus
  • Severe medical disease
  • Life threatening
  • Prior history of drug or alcohol dependence
  • Immunodeficiency
  • Vagotomy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Electroacupuncture (EA)

    Acupoint regimen: Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation using an EA apparatus, with a pair of electrodes connecting acupoints LI4 with PC6, and another pair of electrodes connecting ST36 with SP6. EA stimulation will last for 15 min with a continuous wave of 2 Hz and a current intensity of 0.1-1 mA.

    Procedure: Electroacupuncture (EA)

  • Active comparator
    Laser acupuncture (LA)

    Participants allocated to the LA group will receive LA therapy at the same acupoints used in EA group. The laser will be applied to each point for 40 seconds, which delivered 3 J of energy at each of the acupoints.

    Procedure: Laser acupuncture (LA)

  • Sham comparator
    Sham laser acupuncture (SLA)

    Participants in the control group will receive sham LA treatment without any laser output. The acupuncture points, application duration, and total number of treatments are the same as those in the LA group.

    Procedure: Sham laser acupuncture (SLA)

Interventions

  • ProcedureElectroacupuncture (EA)

    Acupuncture at Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation with a pair of electrodes connecting on LI4/PC6 and ST36/SP6.

  • ProcedureLaser acupuncture (LA)

    The laser applies to each point for 40 seconds, which delivers 3 J of energy at each of the acupoints as those in electroacupuncture group.

  • ProcedureSham laser acupuncture (SLA)

    The laser device without any laser output applies on the acupoints the same as those in the LA group.

06

What researchers measure

Primary outcomes

  1. Length of hospital stay

    Count the total days of hospitalization

    Time frame: up to 24 weeks

Secondary outcomes

  1. CRP

    Inflammatory mediator, CRP

    Time frame: measured at 48 hours, 7 days and 14 days

  2. IL-6

    Inflammatory mediator, IL-6

    Time frame: measured at 48 hours, 7 days and 14 days

  3. TNF-α

    Inflammatory mediator, TNF-α

    Time frame: measured at 48 hours, 7 days and 14 days

  4. IL-1β

    Inflammatory mediator, IL-1β

    Time frame: measured at 48 hours, 7 days and 14 days

  5. IL-10

    Inflammatory mediator, IL-10

    Time frame: measured at 48 hours, 7 days and 14 days

  6. Sequential organ failure assessment (SOFA) score

    The SOFA score is a simple and objective score that allows for calculation of both the number and the severity of organ dysfunction in six organ systems (respiratory, coagulatory, liver, cardiovascular, renal, and neurologic), and the score can measure individual or aggregate organ dysfunction.The SOFA score ranges from 0 to 24; higher scores mean a worse outcome.

    Time frame: measured at 48 hours, 7 days and 14 days

  7. WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) 12-item version

    WHODAS 2.0 is used to measure of disability after major trauma.

    Time frame: measured at 3 and 6 months

  8. Peripheral Blood Mononuclear Cell (PBMC) analysis

    PBMC analysis by flow cytometry

    Time frame: measured at 48 hours, 7 days and 14 days

07

Study locations

1 of 1 sites recruiting
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung City, 833, Taiwan
    Recruiting
08

References and documents

Publications

  • Liu CT, Hsieh TM, Shih FY, Lai WH, Hsieh CH, Wu BY, Chen YH. The effects of electroacupuncture and laser acupuncture therapy for patients with major trauma: A study protocol. Medicine (Baltimore). 2021 Dec 30;100(52):e28367. doi: 10.1097/MD.0000000000028367. PubMed 34967368 ↗

Individual participant data

Plan to share: No — For patient privacy and research confidentiality, temporarily not open.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for May 2024, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2021
First posted
Jul 21, 2021
StartActual
Oct 12, 2021
Primary completionEst.
May 2024
CompletionEst.
Jul 2024
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04970433
Responsible party
Sponsor
First posted
Jul 21, 2021
Start date
Oct 12, 2021
Primary completion
May 2024 (estimated)
Completion
Jul 2024 (estimated)
Last update
Mar 31, 2022

Study contacts

Chun-Ting Liu, Dr.
Contact
juntin0214@gmail.com
0773171232334
Chun-Ting Liu, Dr.
principal investigator · Chang Gung Memorial Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion